Preclinical safety testing of monoclonal antibodies: the significance of species relevance.
about
Immunotoxicity of monoclonal antibodiesPreclinical development of monoclonal antibodies: considerations for the use of non-human primatesBiologics in organ transplantationPractical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodiesWaiving in vivo studies for monoclonal antibody biosimilar development: National and global challengesPioneering better science through the 3Rs: an introduction to the national centre for the replacement, refinement, and reduction of animals in research (NC3Rs)Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28Polymorphisms and interspecies differences of the activating and inhibitory FcγRII of Macaca nemestrina influence the binding of human IgG subclasses.Application of quantitative pharmacology in development of therapeutic monoclonal antibodiesCollagen-induced arthritis in common marmosets: a new nonhuman primate model for chronic arthritisMuscle wasting associated with pathologic change is a risk factor for the exacerbation of joint swelling in collagen-induced arthritis in cynomolgus monkeysAntibody Drug Conjugates: Nonclinical Safety Considerations.Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.Capture, isolation and release of cancer cells with aptamer-functionalized glass bead array.Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor.Pre-clinical toxicity & immunobiological evaluation of DNA rabies vaccine & combination rabies vaccine in rhesus monkeys (Macaca mulatta).Impact of infections and normal flora in nonhuman primates on drug development.Opportunities for the replacement of animals in the study of nausea and vomitingOverview of known non-human primate pathogens with potential to affect colonies used for toxicity testing.Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan.Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.The enhanced pre- and postnatal study for nonhuman primates: update and perspectives.Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals.Drug development and nonclinical to clinical translational databases: past and current efforts.A snapshot of biologic drug development: Challenges and opportunities.Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.Drug Development of Therapeutic Monoclonal Antibodies.Primate autoimmune disease models; lost for translation?A novel preclinical model for rheumatoid arthritis research.The minipig as an alternative non-rodent model for immunogenicity testing using the TNFα blockers adalimumab and infliximab.Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs.Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.
P2860
Q24653374-A589BB31-E97C-4319-8846-3BAEFA89D4EDQ24655266-B7998699-A7ED-4627-B813-9E8329F34357Q26829578-397F5E55-095A-44A5-947E-DDF8641444A7Q27690917-C35D96A3-E202-439B-9E4C-DC412974C9C4Q28079835-38D788CB-C105-471F-A563-7394A911A317Q28650531-E9EAD061-5959-4A88-B8C0-64B63261AB8DQ33573593-E7597273-4AB3-4AA3-BE79-F8B2169A44DBQ33842408-87B89F1F-1BF4-4CAA-AEA7-93EC26681E18Q34293689-FAFDBC97-576F-40E2-9C38-60B44577919EQ34346438-0F27A10A-B63F-454D-AB43-E564B305AC5DQ34802678-02CD1B68-B38D-409F-B062-C0A406E5499CQ35967917-4DEAD40C-03C6-4FF1-A02A-D4C48123D307Q35992509-2BB8FF2E-13C2-4700-8AE0-E58C87327D0BQ36399855-E7934DCA-B03A-41C7-91BD-6DAB8C1603E4Q36579862-35241C9B-B906-42C3-897B-443DD13CC8C8Q37073211-1C1258E2-D414-4E63-9C45-94ED5AF9923FQ37103531-91549C7F-7FA9-4D29-9A80-6445A3418E9BQ37332618-42704E0E-5036-4DD4-8E43-CE08C1652246Q37631601-60AD2D02-D9BA-4BD0-A3A4-1A4CB09C44DAQ37653417-585574E8-D155-47C7-98FB-8E5152F30470Q37947551-F339CB71-1AD4-4B27-A532-0B29D1AED088Q37978260-F8D04223-27A8-48CB-8933-6AAAE58B3AB9Q38061448-1C3A95F3-3749-4F12-AF8D-AC6678D126C6Q38267362-8CA32055-0810-4EF9-9243-D4E6479EAFD7Q38651271-70584B3E-2B62-4324-AFFB-7C00FBD78EB4Q38687397-3353EA32-AB1F-43F9-BC7F-C4108F2EBC8EQ38876360-C3393037-01F7-48CE-89F2-B834D6900FCDQ42292539-225F2BE2-B26D-4206-AA88-60E16CC51EDEQ42640232-955A2DD9-F439-466B-9E2A-4C71FAD7AE6BQ50935053-5CC0358A-EA7D-4D9D-8B0F-B72373AE229CQ51825809-CD2F76B9-35B6-4988-BA81-40A8C8FA0752Q51948632-8E6B0B58-8B8D-4D61-BC83-A52FC9E162AF
P2860
Preclinical safety testing of monoclonal antibodies: the significance of species relevance.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Preclinical safety testing of ...... ificance of species relevance.
@en
Preclinical safety testing of ...... ificance of species relevance.
@nl
type
label
Preclinical safety testing of ...... ificance of species relevance.
@en
Preclinical safety testing of ...... ificance of species relevance.
@nl
prefLabel
Preclinical safety testing of ...... ificance of species relevance.
@en
Preclinical safety testing of ...... ificance of species relevance.
@nl
P2093
P356
P1476
Preclinical safety testing of ...... ificance of species relevance.
@en
P2093
Kathryn Chapman
Mark Graham
Nick Pullen
P2888
P304
P356
10.1038/NRD2242
P577
2007-02-01T00:00:00Z